Relmada Therapeutics Reports Q2 2026 Financial Results
Relmada Therapeutics reported second-quarter 2026 financial results and business updates, including advancing NDV-01 toward an IND target and reporting a $217.7 million cash balance.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day